Windward Capital Management Co. CA increased its position in shares of Pfizer, Inc. (NYSE:PFE) by 0.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 538,658 shares of the biopharmaceutical company’s stock after buying an additional 4,903 shares during the period. Pfizer makes up 3.1% of Windward Capital Management Co. CA’s investment portfolio, making the stock its 10th largest position. Windward Capital Management Co. CA’s holdings in Pfizer were worth $18,093,000 as of its most recent filing with the SEC.
Other hedge funds also recently made changes to their positions in the company. Orbimed Advisors LLC boosted its stake in shares of Pfizer by 46.3% in the fourth quarter. Orbimed Advisors LLC now owns 5,167,900 shares of the biopharmaceutical company’s stock worth $167,853,000 after buying an additional 1,635,700 shares during the period. Paulson & CO. Inc. bought a new stake in shares of Pfizer during the fourth quarter worth approximately $11,439,000. E&G Advisors LP boosted its stake in shares of Pfizer by 6.8% in the first quarter. E&G Advisors LP now owns 62,258 shares of the biopharmaceutical company’s stock worth $2,130,000 after buying an additional 3,940 shares during the period. Prentiss Smith & Co. Inc. boosted its stake in shares of Pfizer by 1.7% in the first quarter. Prentiss Smith & Co. Inc. now owns 14,948 shares of the biopharmaceutical company’s stock worth $511,000 after buying an additional 250 shares during the period. Finally, Carroll Financial Associates Inc. boosted its stake in shares of Pfizer by 33.9% in the first quarter. Carroll Financial Associates Inc. now owns 197,820 shares of the biopharmaceutical company’s stock worth $6,767,000 after buying an additional 50,045 shares during the period. 69.95% of the stock is owned by institutional investors.
Pfizer, Inc. (PFE) opened at 33.54 on Friday. The company has a market capitalization of $200.16 billion, a PE ratio of 28.23 and a beta of 1.01. The stock’s 50 day moving average is $33.20 and its 200 day moving average is $33.25. Pfizer, Inc. has a 52 week low of $29.83 and a 52 week high of $37.39. Pfizer also was the target of unusually large options trading on Tuesday. Investors purchased 21,983 put options on the stock. This represents an increase of approximately 351% compared to the average daily volume of 4,871 put options.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.67 by $0.02. Pfizer had a return on equity of 23.68% and a net margin of 13.76%. The business had revenue of $12.78 billion during the quarter, compared to the consensus estimate of $13.09 billion. During the same quarter in the prior year, the company posted $0.67 earnings per share. Pfizer’s revenue was down 1.7% compared to the same quarter last year. Analysts predict that Pfizer, Inc. will post $2.55 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, September 1st. Investors of record on Friday, August 4th will be issued a dividend of $0.32 per share. The ex-dividend date of this dividend is Wednesday, August 2nd. This represents a $1.28 annualized dividend and a yield of 3.82%. Pfizer’s dividend payout ratio (DPR) is currently 108.48%.
ILLEGAL ACTIVITY NOTICE: This story was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://stocknewstimes.com/2017/07/21/windward-capital-management-co-ca-has-18-09-million-position-in-pfizer-inc-pfe.html.
PFE has been the subject of a number of recent analyst reports. Sanford C. Bernstein set a $39.00 price target on Pfizer and gave the company a “buy” rating in a research note on Monday. BidaskClub raised Pfizer from a “strong sell” rating to a “sell” rating in a research note on Friday, June 23rd. Jefferies Group LLC reaffirmed a “neutral” rating and issued a $35.00 price target (up from $34.00) on shares of Pfizer in a research note on Thursday, April 13th. Morgan Stanley reaffirmed a “neutral” rating and issued a $38.00 price target on shares of Pfizer in a research note on Thursday, April 6th. Finally, Societe Generale reaffirmed a “neutral” rating and issued a $36.00 price target on shares of Pfizer in a research note on Thursday, March 23rd. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and ten have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $37.68.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
